SIRPA and glioblastoma: In addition to targeting the CD47/SIRPα axis, inhibition of BACE1 by drugs promoted MDM-mediated phagocytosis of GSCs (inhibitor MK-8931), which also affected the progression of GBM in vivo (Fig. 3).